NRG-GY037: A Phase III Study of Induction Pembrolizumab and Chemotherapy Followed by Chemoradiation and Pembrolizumab Versus Chemoradiation and Pembrolizumab Both Followed by Pembrolizumab for High Risk Locally Advanced Cervical Cancer
NRG-GY037: A Phase III Study of Induction Pembrolizumab and Chemotherapy Followed by Chemoradiation and Pembrolizumab Versus Chemoradiation and Pembrolizumab Both Followed by Pembrolizumab for High Risk Locally Advanced Cervical Cancer
This phase III trial compares the addition of induction chemotherapy, with carboplatin, paclitaxel and pembrolizumab, to chemotherapy and radiation, with cisplatin and pembrolizumab followed by pembrolizumab maintenance for the treatment of patients with cervical cancer that has spread to nearby tissue or lymph nodes (locally advanced). Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Paclitaxel is in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of cancer cells. Adding induction chemotherapy to the usual treatment of chemotherapy and radiation followed by maintenance may be more effective in treating patients with high risk, locally advanced cervical cancer.
PRIMARY OBJECTIVE:
I. To determine whether induction immunotherapy (IO) and chemotherapy prior to concurrent chemoradiation therapy (CCRT) + IO improves progression-free survival (PFS) compared to CCRT+IO alone.
SECONDARY OBJECTIVES:
I. To assess whether induction IO and chemotherapy prior to CCRT+IO improves the overall survival (OS) compared to CCRT+IO alone.
II. To determine the nature and degree of toxicity of induction IO and chemotherapy prior to CCRT + IO as compared to concurrent CCRT+IO as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version (v) 5.0.
III. To determine the impact on CCRT start, CCRT completion time, and number of cycles of cisplatin administered; with induction IO and chemotherapy prior to CCRT+IO arm as compared to CCRT+IO.
IV. To assess the association between allostatic load and PFS/OS. V. To assess the predictive value of the integrated biomarker: PD-L1 expression at baseline for progression free survival.
VI. To assess the prognostic and predictive value of the integrated biomarker: circulating tumor deoxyribonucleic acid (ctDNA) at baseline and at 3 months post radiation therapy (RT) for progression free survival.
VII. To explore radiotherapy quality pretreatment scores conducted by expert review with assistance from artificial intelligence (AI) models and correlation with outcomes.
EXPLORATORY OBJECTIVES:
I. To assess the evolution of T cell receptor (TCR) repertoire on treatment and its correlation with clinical outcomes.
II. To identify pre-treatment tumor microenvironment biomarkers predictive of outcomes.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM 1:
CHEMORADIATION: Patients receive cisplatin intravenously (IV) once weekly (QW) for 5 weeks and pembrolizumab IV over 30 minutes every 3 weeks (Q3W) for 5 doses. Patients also undergo radiation therapy once daily 5 days per week for 25-29 treatments in weeks 1-5 followed by brachytherapy up to twice per week for 4-5 treatments in weeks 5-7. Treatment is given in the absence of disease progression or unacceptable toxicity
MAINTENANCE: Patients receive pembrolizumab IV over 30 minutes every 6 weeks (Q6W) for 15 cycles in the absence of disease progression or unacceptable toxicity.
Patients undergo positron emission tomography (PET) scan, computed tomography (CT) scan, chest x-ray and/or magnetic resonance imaging (MRI) and blood sample collection throughout the study.
ARM 2:
INDUCTION: Patients receive carboplatin IV and paclitaxel IV QW on weeks 1-3 and pembrolizumab IV over 30 minutes Q3W on weeks 1 for each cycle. Cycles repeat every 3 weeks for 2 cycles in the absence of disease progression or unacceptable toxicity.
CHEMORADIATION: Patients receive cisplatin IV QW for 5 weeks and pembrolizumab IV over 30 minutes every Q3W for 5 doses. Patients also undergo radiation therapy once daily 5 days per week for 25-29 treatments in weeks 7-11 followed by brachytherapy up to twice per week for 4-5 treatments in weeks 11-13. Treatment is given in the absence of disease progression or unacceptable toxicity
MAINTENANCE: Patients receive pembrolizumab IV over 30 minutes Q6W for 14 cycles in the absence of disease progression or unacceptable toxicity.
Patients undergo PET scan, CT scan, chest x-ray and/or MRI and blood sample collection throughout the study.
After completion of study treatment, patients are followed up every 3 months for 2 years then every 6 months for 3 years.
Inclusion Criteria:
Patients must have pathologically confirmed newly diagnosed cervical cancer. Eligible pathologic types: squamous cell carcinoma, adenocarcinoma, adenosquamous cell carcinoma
Patients must have locally advanced cervical cancer (LACC) with T3 or T4 disease with or without lymph node involvement:
No paraaortic lymph node (PALN) metastases above the T12/L1 interspace.
Radiologic definition of lymph node staging:
N1:
N2:
One or more para-aortic lymph node with short axis diameter of ≥ 15 mm (axial plane) by CT or MRI, and/or
One or more para-aortic lymph node with short axis diameter of ≥ 10 mm and SUVmax ≥ 2.5 by FDG-PET
Birmingham, Alabama 35233, United States
gingerreeves@uabmc.edu
Irvine, California 92612, United States
Orange, California 92868, United States
Coral Gables, Florida 33146, United States
Coral Springs, Florida 33065, United States
Deerfield Beach, Florida 33442, United States
Hollywood, Florida 33021, United States
Hollywood, Florida 33021, United States
Miami, Florida 33136, United States
North Miami, Florida 33181, United States
Plantation, Florida 33324, United States
Peoria, Illinois 61615, United States
Indianapolis, Indiana 46202, United States
Clive, Iowa 50325, United States
Des Moines, Iowa 50309, United States
Des Moines, Iowa 50314, United States
Overland Park, Kansas 66210, United States
Overland Park, Kansas 66211, United States
Metairie, Louisiana 70006, United States
Columbia, Maryland 21044, United States
Easton, Maryland 21601, United States
Glen Burnie, Maryland 21061, United States
Ann Arbor, Michigan 48106, United States
Brighton, Michigan 48116, United States
Lee's Summit, Missouri 64064, United States
Lebanon, New Hampshire 03756, United States
Forest Hills, New York 11375, United States
New York, New York 10016, United States
Syracuse, New York 13210, United States
Chapel Hill, North Carolina 27599, United States
Charlotte, North Carolina 28203, United States
Huntersville, North Carolina 28078, United States
Kernersville, North Carolina 27284, United States
Supply, North Carolina 28462, United States
Wilmington, North Carolina 28401, United States
Wilmington, North Carolina 28401, United States
Cincinnati, Ohio 45219, United States
Franklin, Ohio 45005-1066, United States
West Chester, Ohio 45069, United States
Tulsa, Oklahoma 74146, United States
Bethlehem, Pennsylvania 18015, United States
Harrisburg, Pennsylvania 17109, United States
Johnstown, Pennsylvania 15901, United States
Mechanicsburg, Pennsylvania 17050, United States
Wilkes-Barre, Pennsylvania 18711, United States
Charleston, West Virginia 25304, United States
Madison, Wisconsin 53718, United States
Madison, Wisconsin 53792, United States
research@hogonc.com479-872-8100
501-686-8274
research@hogonc.com479-872-8130
research@hogonc.com479-872-8130
clinical.trials@kp.org800-398-3996
becomingapatient@coh.org626-256-4673
becomingapatient@coh.org800-826-4673
clinical.trials@kp.org800-398-3996
ucstudy@uci.edu877-827-8839
877-467-3411
clinical.trials@kp.org800-398-3996
cancercto@ucsd.edu858-822-5354
clinical.trials@kp.org800-398-3996
clinical.trials@kp.org800-398-3996
ucstudy@uci.edu877-827-8839
clinical.trials@kp.org800-398-3996
clinical.trials@kp.org800-398-3996
clinical.trials@kp.org800-398-3996
becomingapatient@coh.org800-826-4673
becomingapatient@coh.org800-826-4673
clinical.trials@kp.org800-398-3996
720-848-0650
720-848-0650
833-223-4732
jennifer.long@norwalkhealth.org203-852-2996
research@beebehealthcare.org302-291-6730
lbarone@christianacare.org302-623-4450
lbarone@christianacare.org302-623-4450
research@beebehealthcare.org302-291-6730
305-243-2647
305-243-2647
305-243-2647
kginnity@med.miami.edu
Allison.bruce@nemours.org302-651-5572
OHR@mhs.net954-265-1847
305-243-2647
305-243-2647
305-243-2647
kginnity@med.miami.edu
Roster@nrgoncology.org412-339-5294
CancerClinicalTrials@orlandohealth.com321-841-7246
954-265-4325
305-243-2647
ClinicalTrials@moffitt.org800-679-0775
ClinicalTrials@moffitt.org800-679-0775
ClinicalTrials@moffitt.org800-679-0775
ClinicalTrials@moffitt.org800-679-0775
ClinicalTrials@moffitt.org800-679-0775
888-946-7447
ORS@piedmont.org404-425-7943
404-778-1868
clinicaltrialsoncology@dekalbmedical.org440-778-1868
770-400-6629
stephanie.couch@stjoeshealth.org734-712-3671
eslinget@slhs.org208-381-2774
stephanie.couch@stjoeshealth.org734-712-3671
eslinget@slhs.org208-381-2774
eslinget@slhs.org208-381-2774
mccinfo@mtcancer.org406-969-6060
eslinget@slhs.org208-381-2774
cancer@northwestern.edu312-695-1301
Cancer_Studies@rush.edu312-226-2371
312-355-3046
Research@Carle.com800-446-5532
morganthaler.jodi@mhsil.com217-876-4762
morganthaler.jodi@mhsil.com217-876-4762
Donald.Smith3@nm.org630-352-5360
Research@carle.com800-446-5532
Donald.Smith3@nm.org630-352-5360
Research@carle.com800-446-5532
708-226-4357
nctnprogram_rhlccc@northwestern.edu
nctnprogram_rhlccc@northwestern.edu
andersonj@illinoiscancercare.com309-243-3605
andersonj@illinoiscancercare.com309-243-3605
lkline@uwhealth.org779-696-9378
217-545-7929
800-444-7541
pallante.beth@mhsil.com217-528-7541
Research@carle.com800-446-5532
Donald.Smith3@nm.org630-352-5360
844-793-0745
iutrials@iu.edu317-278-5632
CancerResearch@powershealth.org219-836-6879
219-924-8178
877-784-4673
219-947-1795
CancerResearch@COMHS.org219-836-6875
iutrials@iu.edu317-278-5632
iutrials@iu.edu317-278-5632
219-836-3349
mnicholson@comhs.org219-934-8869
CancerResearch@COMHS.org219-836-6875
515-241-3305
319-365-4673
319-363-2690
515-241-3305
515-241-6727
515-241-3305
515-241-3305
515-241-3305
800-237-1225
515-241-3305
KUCC_Navigation@kumc.edu913-588-3671
KUCC_Navigation@kumc.edu913-588-3671
KUCC_Navigation@kumc.edu913-588-3671
KUCC_Navigation@kumc.edu913-588-3671
859-257-3379
emede1@lsuhsc.edu504-210-3539
emede1@lsuhsc.edu504-210-3539
emede1@lsuhsc.edu504-210-3539
emede1@lsuhsc.edu504-210-3539
Elisemarie.curry@ochsner.org504-842-8084
Elisemarie.curry@ochsner.org504-842-8084
Roster@nrgoncology.org412-339-5294
clinicalresearch@mainehealth.org207-396-8670
207-459-1600
clinicalresearch@mainehealth.org207-396-8670
800-888-8823
443-643-3010
443-546-1300
Christina.weisenborn@umm.edu410-822-1000
410-553-8100
Sarah.Larson@umm.edu301-755-4397
Jeanmarie.downing@umm.edu410-337-4569
MCRCwebsitecontactform@stjoeshealth.org734-712-7251
CancerAnswerLine@med.umich.edu800-865-1125
MCRCwebsitecontactform@stjoeshealth.org734-712-7251
800-865-1125
MCRCwebsitecontactform@stjoeshealth.org734-712-7251
MCRCwebsitecontactform@stjoeshealth.org734-712-7251
crcwm-regulatory@crcwm.org616-391-1230
crcwm-regulatory@crcwm.org616-391-1230
harsha.trivedi@umhsparrow.org517-364-3712
MCRCwebsitecontactform@stjoeshealth.org734-712-7251
CancerTrials@EssentiaHealth.org218-786-3308
CancerTrials@EssentiaHealth.org218-786-3308
CancerTrials@EssentiaHealth.org218-786-3308
CancerTrials@EssentiaHealth.org218-786-3308
218-786-3308
mmcorc@healthpartners.com952-993-1517
CancerTrials@EssentiaHealth.org218-786-3308
CancerTrials@EssentiaHealth.org218-786-3308
LJCrockett@freemanhealth.com417-347-4030
913-588-3671
KUCC_Navigation@kumc.edu913-588-3671
KUCC_Navigation@kumc.edu913-588-3671
research@phelpshealth.org573-458-7504
417-269-4520
314-251-7066
research@billingsclinic.org800-996-2663
402-354-5144
unmcrsa@unmc.edu402-559-6941
702-851-4672
cancer.research.nurse@dartmouth.edu800-639-6918
212-639-7592
856-325-6757
Roster@nrgoncology.org412-339-5294
mary.danish@rwjbh.org732-923-6564
212-639-7592
212-639-7592
732-235-7356
732-235-7356
clinicaltrials@capitalhealth.org609-394-4130
Lennette.Gonzales@rwjbh.org732-557-8294
HSC-ClinicalTrialInfo@salud.unm.edu505-925-0348
516-734-8896
askroswell@roswellpark.org800-767-9355
212-639-7592
nhppflushing@northwell.edu718-559-3600
718-520-6620
516-734-8896
212-639-7592
516-734-8896
cancertrials@nyulangone.org212-263-4432
AMellor@northwell.edu914-666-1366
CCTO@mssm.edu212-824-7309
CancerTrials@nyulangone.org
CCTO@mssm.edu212-824-7309
212-434-4460
212-639-7592
516-734-8896
BinghamE@upstate.edu315-464-3603
718-312-3446
914-366-1600
718-226-8888
800-862-2215
315-464-5476
BinghamE@upstate.edu315-464-3603
eskwak@montefiore.org718-379-6866
eskwak@montefiore.org718-379-6866
eskwak@montefiore.org718-379-6866
212-639-7592
McDowelE@upstate.edu315-464-8230
cancerclinicaltrials@med.unc.edu877-668-0683
800-804-9376
kashah@novanthealth.org980-201-6360
800-804-9376
888-275-3853
800-804-9376
kashah@novanthealth.org980-201-6360
asmarrs@novanthealth.org336-718-8335
kashah@novanthealth.org980-201-6360
919-785-4878
910-754-4716
910-251-1839
910-342-3000
pjordan@novanthealth.org336-718-8335
336-713-6771
CTUReferral@UHhospitals.org800-641-2422
ClinicalReserachDept@aultman.com330-363-7274
clinical.trials@daytonncorp.org937-528-2900
CTUReferral@UHhospitals.org800-641-2422
cancer@uchealth.com513-584-7698
CTUReferral@UHhospitals.org800-641-2422
TaussigResearch@ccf.org866-223-8100
Jamesline@osumc.edu800-293-5066
clinical.trials@daytonncorp.org937-528-2900
clinical.trials@daytonncorp.org937-528-2900
clinical.trials@daytonncorp.org937-528-2900
937-569-7515
TaussigResearch@ccf.org866-223-8100
CTUReferral@UHhospitals.org800-641-2422
CTUReferral@UHhospitals.org800-641-2422
PCIOncResearch@promedica.org419-824-1842
clinical.trials@daytonncorp.org937-528-2900
cancer@uchealth.com513-584-7698
CTUReferral@UHhospitals.org800-641-2422
ou-clinical-trials@ouhsc.edu405-271-8777
918-505-3200
CanRsrchStudies@providence.org503-215-2614
CanRsrchStudies@providence.org503-215-2614
CanRsrchStudies@providence.org503-215-2614
cancer@lhs.org800-220-4937
CanRsrchStudies@providence.org503-215-2614
CanRsrchStudies@providence.org503-215-2614
information@kpchr.org503-335-2400
trials@ohsu.edu503-494-1080
503-413-1742
Morgan_M.Horton@lvhn.org610-402-9543
610-776-4714
484-503-4151
Morgan_M.Horton@lvhn.org610-402-9543
cancerresearch@geisinger.edu570-271-5251
cancerresearch@geisinger.edu877-204-6081
Morgan_M.Horton@lvhn.org610-402-9543
Roster@nrgoncology.org412-339-5294
ClinicalResearchServices@upmc.edu412-864-7716
724-838-1900
klitchfield@PINNACLEHEALTH.org717-724-6765
CTO@hmc.psu.edu717-531-3779
haneydl@upmc.edu412-389-5208
ddefazio@wpahs.org412-359-3043
814-534-4724
cancerresearch@geisinger.edu570-523-9200
haneydl@upmc.edu412-389-5208
412-858-7746
ONCTrialNow@jefferson.edu215-600-9151
215-728-4790
215-728-2983
877-284-2000
412-647-2811
412-578-5000
412-367-6454
610-776-4714
814-676-7900
Roster@nrgoncology.org412-339-5294
Dawnmarie.DeFazio@ahn.org
HemonCCTrials@geisinger.edu570-271-5251
ONCTrialNow@jefferson.edu215-600-9151
401-274-1122
hcc-clinical-trials@musc.edu843-792-9321
kmertz-rivera@gibbscc.org864-560-6104
kmertz-rivera@gibbscc.org864-560-6104
kmertz-rivera@gibbscc.org864-560-6104
OncRegulatory@avera.org605-322-3095
canceranswerline@UTSouthwestern.edu214-590-5582
canceranswerline@UTSouthwestern.edu214-648-7097
canceranswerline@UTSouthwestern.edu214-648-7097
Suzanne.cole@utsouthwestern.edu972-669-7044
cancerinfo@hci.utah.edu888-424-2100
cancerinfo@hci.utah.edu888-424-2100
cancerinfo@hci.utah.edu888-424-2100
Stephanie.VanBebber@inova.org703-776-2580
uvacancertrials@hscmail.mcc.virginia.edu434-243-6303
Stephanie.VanBebber@inova.org703-720-5210
Stephanie.VanBebber@inova.org703-720-5210
Stephanie.VanBebber@inova.org703-208-6650
Keary.janet@inova.org703-858-6000
CTOclinops@vcu.edu804-628-6430
540-981-7377
800-804-8824
503-413-2150
304-388-9944
cancertrialsinfo@hsc.wvu.edu304-293-7374
cancertrialsinfo@hsc.wvu.edu304-293-7374
CancerTrials@EssentiaHealth.org218-786-3308
CancerTrials@EssentiaHealth.org218-786-3308
clinicaltrials@cancer.wisc.edu800-622-8922
clinicaltrials@cancer.wisc.edu800-622-8922
414-805-3666
research.institute@phci.org
mmcorc@healthpartners.com952-993-1517
262-928-7878
701-364-6272
Chanda.miller@phci.org262-928-5539